Clinical Trials on Advanced NSCLC in United Kingdom
Total 3001 results
-
Shanghai Huaota Biopharmaceutical Co., Ltd.RecruitingNSCLC | Advanced Solid TumorUnited States, China
-
Jacobio Pharmaceuticals Co., Ltd.RecruitingNSCLC | Advanced Solid Tumor | CRCUnited States
-
Hatim HusainActive, not recruitingAdvanced NSCLCUnited States
-
Mythic TherapeuticsRecruitingNon-Small Cell Lung Cancer | NSCLC | Advanced Non-Small Cell Lung Cancer | NSCLC Stage IV | NSCLC Stage IIIB | Advanced Non-Small Cell Squamous Lung Cancer | Advanced Non-Small Cell Non-Squamous Lung CancerUnited States, Australia, Korea, Republic of, United Kingdom
-
Regeneron PharmaceuticalsRecruiting
-
University of California, Los AngelesUniversity of California, San Francisco; University of California, IrvineActive, not recruitingAdvanced Cancer | Advance Care Planning | Advance DirectivesUnited States
-
AmgenNo longer availableNon Small-cell Lung Cancer | Locally Advanced Unresectable NSCLC | Locally Advanced Metastatic NSCLCUnited States, Taiwan, Israel, Saudi Arabia, Brazil, Argentina
-
AstraZenecaCompletedCaucasian Patients With EGFR Mutation Positive Advanced NSCLCBulgaria, Italy, Poland, Spain, Turkey, United Kingdom, Romania, Norway, Hungary, Portugal, Greece, Switzerland, France
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of Sheffield; Weston Park Hospital Cancer Charity; Sheffield Hospitals...Completed
-
Jun Zhang, MD, PhDGenentech, Inc.; ExelixisNot yet recruitingLung Cancer | NSCLC Stage IV | Advanced NSCLC | Metastatic NSCLC - Non-Small Cell Lung CancerUnited States
-
Mt. Sinai Medical Center, MiamiAmgenCompletedUnresectable Locally Advanced NSCLCUnited States
-
Palobiofarma SLOhio State UniversityActive, not recruiting
-
Aegera TherapeuticsTerminated
-
Mirati Therapeutics Inc.Aadi Bioscience, Inc.Active, not recruitingNSCLC | Metastatic Cancer | Advanced Cancer | Solid Tumor, Adult | Malignant Neoplastic DiseaseUnited States
-
University College, LondonRecruiting
-
AstraZenecaParexelTerminatedAdvanced Solid TumorsUnited Kingdom
-
Eli Lilly and CompanyCompletedAdvanced CancerUnited Kingdom
-
Cancer Research UKCompleted
-
AstraZenecaCompletedAdvanced Solid MalignanciesUnited Kingdom
-
PfizerActive, not recruitingOvarian Cancer | NSCLC | Solid Tumors | Urothelial Cancer | Advanced MalignanciesHungary, Spain, United States, Canada, Taiwan, Japan, Serbia, Italy, New Zealand, Australia, Mexico, Russian Federation, United Kingdom, France, Korea, Republic of, Belgium, Poland, Denmark, Israel
-
BeiGeneCompletedAdvanced Solid TumorsUnited Kingdom
-
ArQule, Inc. (a wholly owned subsidiary of Merck...CompletedCancer, Advanced Solid TumorsUnited Kingdom
-
PfizerCompletedAdvanced Non-Hematologic MalignanciesUnited Kingdom
-
AmgenActive, not recruitingKRAS p, G12c Mutated /Advanced Metastatic NSCLCFinland, United States, Canada, Belgium, Spain, Korea, Republic of, Netherlands, United Kingdom, Australia, Denmark, Hungary, Sweden, Taiwan, Greece, Russian Federation, Switzerland, France, Italy, Japan, Poland, Brazil, Germany, Po...
-
Stemline Therapeutics, Inc.CompletedStudy of the PI3K Inhibitor SL-901 in Patients With Advanced Solid Tumors With Advanced Solid TumorsAdvanced Solid TumorUnited Kingdom
-
Cancer Research UKTerminatedAdvanced Solid TumoursUnited Kingdom
-
AstraZenecaParexelTerminatedAdvanced Solid TumoursUnited Kingdom, United States
-
PharmaMarCompletedAdvanced Solid TumorsUnited Kingdom, Switzerland
-
Royal Marsden NHS Foundation TrustAstraZeneca; Institute of Cancer Research, United KingdomCompleted
-
AstraZenecaCompletedLocally Advanced or Metastatic NSCL Cancer Stage IIIB IVUnited Kingdom
-
Heidelberg Pharma AGTerminatedAdvanced Solid TumoursUnited Kingdom
-
Royal Marsden NHS Foundation TrustAstraZeneca; Institute of Cancer Research, United KingdomCompletedAdvanced CancerUnited Kingdom
-
Nerviano Medical SciencesTerminatedAdvanced/Metastatic Solid TumorsUnited Kingdom, France
-
PharmaMarCompletedSpecific Advanced Solid TumorsSpain, United Kingdom
-
BeiGeneRecruitingLocally Advanced or Metastatic Solid Tumors for Phase 1,Dose Escalation and Phase 2 Safety Lead-in, HNSCC, NSCLC and RCC Participants for Phase 2Australia, United States, Spain, France, Italy, Korea, Republic of, Poland
-
Royal Marsden NHS Foundation TrustInstitute of Cancer Research, United KingdomUnknownAdvanced Solid MalignanciesUnited Kingdom
-
King's College LondonCalouste Gulbenkian Foundation; Centro Hospitalar Lisboa CentralCompletedAdvanced CancerUnited Kingdom
-
Eisai Inc.Completed
-
King's College LondonPrincess Alice HospiceCompleted
-
Liverpool University Hospitals NHS Foundation TrustUniversity of LiverpoolCompleted
-
AstraZenecaParexelCompletedAdvanced MalignanciesUnited Kingdom, United States
-
Heidelberg Pharma AGTerminatedAdvanced Solid TumoursUnited Kingdom
-
University College, LondonActive, not recruitingGynecologic Cancer | Advanced Cancer | Clear Cell TumorUnited Kingdom
-
Jun Zhang, MD, PhDRhode Island HospitalRecruitingNSCLC, Stage III | Locally Advanced Lung CarcinomaUnited States
-
T3 Pharmaceuticals AGRecruiting
-
zr Pharma & GmbHCompletedAdvanced Solid TumorsUnited Kingdom
-
AstraZenecaSyneos HealthCompletedAdvanced Solid TumoursUnited States, Spain, Korea, Republic of, United Kingdom
-
Taiho Oncology, Inc.TerminatedAdvanced Solid TumorsItaly, Spain, United States, Netherlands, United Kingdom
-
Millennium Pharmaceuticals, Inc.CompletedAdvanced Nonhematologic MalignanciesUnited States, Spain, United Kingdom
-
OSI PharmaceuticalsCompletedAdvanced Solid TumorsUnited States, United Kingdom